Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: From the Danish 'MALOVA' ovarian cancer study

APMIS

Volumn 118, Issue 8, 2010, Pages 557-564

  Høgdall, Estrid V S ^a,b   Christensen, Lise ^b   Kjaer, Susanne K ^a,b   Blaakaer, Jan ^c   Christensen, Ib Jarle ^b   Høgdall, Claus K ^b  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

BCl 2; immunohistochemistry; ovarian cancer; prognosis; Tissue array

Indexed keywords

PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RATING SCALE;

DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS;

EID: 77954710590     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02614.x     Document Type: Article

References (25)

1. Kjaerbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK. Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002 - comparison with other Nordic countries. Acta Obstet Gynecol Scand 2005 84 : 1006 1012.
2. Kjaer SK, Ewertz M. Ovariecancer i Danmark 1943-1982: kræftstatistik nr. 20. Ugeskr Laeger 1987 149 : 3356 3360.
3. Kjaer SK, Storm HH. Female genital organs. Survival of Danish Cancer Patients 1943-87. APMIS 1993 33 : 107 121.
4. Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005 113 : 977 990.
5. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology (Huntingt) 2005 68 : 293 298.
6. Nielsen MLS, Høgdall CK. The Danish Gynecologic Cancer Database - A Nationwide Clinical Database for Ovarian Cancer, Endometrial Cancer and Cervical Cancer, Year 2006-2007. Copenhagen: Lægeforeningens Forlag, 2008. (ISSN 19017877). (in press)
7. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004 10 : 3291 3300.
8. Rapkiewicz AV, Espina V, Petricoin EF, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004 40 : 2604 2612.
9. Arrends MJ, Willie AH. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 1991 32 : 223 224.
10. Raspollini MR, Amunni G, Villanucci A, Castiglione F, Degl'Innocenti DR, Baroni G, et al. HER-2/neu and bcl-2 in Ovarian carcinoma. Clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol 2006 14 : 181 186.
11. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996 56 : 2178 2184.
12. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000 77 : 278 282.
13. Sengupta PS, McGown AT, Bajaj V, Blackhall F, Swindell R, Bromley M, et al. P53 and related proteins in epithelial ovarian cancer. Eur J Cancer 2000 36 : 2317 2328.
14. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996 105 : 341 349.
15. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995 72 : 1324 1329.
16. Sagarra RAM, Andrade LALA, Matinez EZ, Pinto GA, Syrjänen KJ, Derchain SFM. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer 2002 12 : 720 727.
17. Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachów J, Karpinska G, et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEKI expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 2003 88 : 848 854.
18. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004 36 : 295 300.
19. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001 94 : 1 5.
20. Høgdall EV, Christensen L, Høgdall CK, Frederiksen K, Gayther S, Blaakaer J, et al. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significancer in ovarian carcinomas. APMIS 2008 116 : 400 409.
21. Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, et al. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study. Cancer 2003 9 : 2387 2395.
22. Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, et al. Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006 15 : 798 803.
23. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972 34 : 187 220.
24. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical cormparison between low-grade and high-grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005 29 : 1034 1041.
25. Preethi TR, Chacko P, Kesari AL, Praseeda I, Chellam VG, Pillai MR. Apoptosis in epithelial ovarian tumors. Pathol Res Pract 2002 198 : 273 280.